Connect your AI

TTRX TTRX Warrants and Rights Outstanding

Warrants and Rights Outstanding at other companies

Tarsus Pharmaceuticals, Inc.TARS

312.5K0.0%

Other financials

Income statement

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

Operating cash flow-$1.6M-448%

Valuation

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TTRX's warrants and rights outstanding?: TTRX (TTRX) reported warrants and rights outstanding of 1.2M in Q1 2026.